Patrícia Krauze De Almeida
Biographic Data
| ID | 1683290 |
|---|---|
| NAME | Patrícia Krauze De Almeida |
| GIVEN NAMES | Patrícia Krauze |
| FAMILY NAME | De Almeida |
| SIGNATURE | DE ALMEIDA P K |
| AFFILIATIONS | Fundação Oswaldo Cruz |
| ORCID | 0000-0002-9554-4451 |
| VERIFIED | Yes |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 4 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2025 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
High-cost medicine litigation in Brazil
Brazil has no established or universally adopted definition for high-cost medicines (HCM). The study mapped the profile and participation of HCM among those cited in the scientific and academic output on health litigation. A scoping review followed the methodology proposed by the Joanna Briggs Institute, searching Medline, Embase, LILACS, Web of Science, and Scopus databases, besides the Digital Library of Dissertations and Theses, for empirical …
Medicamentos de Alto Custo
O estudo objetivou identificar as definições e compreensões existentes sobre Medicamentos de Alto Custo (MAC) na produção científica e acadêmica brasileira relacionada à judicialização de medicamentos. A revisão de escopo seguiu a metodologia proposta pelo Joanna Briggs Institute. As bases bibliográficas Medline, Embase, Lilacs, Web of Science e Scopus, e a Biblioteca Digital de Teses e Dissertações foram pesquisadas em busca de estudos empíricos…
Definitions of high-cost medicines present in Brazilian scientific and academic literature on health judicialization
The study aimed to single out definitions and interpretations regarding high-cost medicines in the scientific and academic literature on health litigation. A scoping review followed the methodology proposed by the Joanna Briggs Institute. MEDLINE, EMBASE, LILACS, Web of Science and Scopus, and the Digital Library of Dissertations and Theses were searched for empirical studies on litigation for access to medicines that included high-cost drugs, pu…
Judicialização de medicamentos de alto custo no Brasil
No Brasil, não existe definição estabelecida e universalmente adotada para medicamentos de alto custo (MAC). Mapearam-se perfil e representatividade dos MAC na produção científica e acadêmica nacional sobre judicialização. A revisão de escopo seguiu metodologia do Joanna Briggs Institute nas bases bibliográficas Medline, Embase, Lilacs, Web of Science e Scopus, e na Biblioteca Digital de Teses e Dissertações, resgatando estudos empíricos relacion…
No prominent works on this page.
High-cost medicine litigation in Brazil
Brazil has no established or universally adopted definition for high-cost medicines (HCM). The study mapped the profile and participation of HCM among those cited in the scientific and academic output on health litigation. A scoping review followed the methodology proposed by the Joanna Briggs Institute, searching Medline, Embase, LILACS, Web of Science, and Scopus databases, besides the Digital Library of Dissertations and Theses, for empirical …
Medicamentos de Alto Custo
O estudo objetivou identificar as definições e compreensões existentes sobre Medicamentos de Alto Custo (MAC) na produção científica e acadêmica brasileira relacionada à judicialização de medicamentos. A revisão de escopo seguiu a metodologia proposta pelo Joanna Briggs Institute. As bases bibliográficas Medline, Embase, Lilacs, Web of Science e Scopus, e a Biblioteca Digital de Teses e Dissertações foram pesquisadas em busca de estudos empíricos…
Definitions of high-cost medicines present in Brazilian scientific and academic literature on health judicialization
The study aimed to single out definitions and interpretations regarding high-cost medicines in the scientific and academic literature on health litigation. A scoping review followed the methodology proposed by the Joanna Briggs Institute. MEDLINE, EMBASE, LILACS, Web of Science and Scopus, and the Digital Library of Dissertations and Theses were searched for empirical studies on litigation for access to medicines that included high-cost drugs, pu…
Judicialização de medicamentos de alto custo no Brasil
No Brasil, não existe definição estabelecida e universalmente adotada para medicamentos de alto custo (MAC). Mapearam-se perfil e representatividade dos MAC na produção científica e acadêmica nacional sobre judicialização. A revisão de escopo seguiu metodologia do Joanna Briggs Institute nas bases bibliográficas Medline, Embase, Lilacs, Web of Science e Scopus, e na Biblioteca Digital de Teses e Dissertações, resgatando estudos empíricos relacion…
Medical Malpractice and Liability Issues (4 works) · Public Health in Brazil (4 works) · Health Systems, Economic Evaluations, Quality of Life (2 works) · Political science (2 works) · Brazilian Legal Issues (1 works) · Ethics and bioethics in healthcare (1 works) · Humanities (1 works) · Philosophy (1 works)